Seer (NASDAQ:SEER) Shares Down 0.5% – What’s Next?

Shares of Seer, Inc. (NASDAQ:SEER) were down 0.5% during mid-day trading on Wednesday . The company traded as low as $1.93 and last traded at $1.94. Approximately 147,503 shares changed hands during mid-day trading, a decline of 25% from the average daily volume of 195,644 shares. The stock had previously closed at $1.95.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Seer in a research note on Friday, July 17th. Two research analysts have rated the stock with a Strong Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $4.00.

Seer Price Performance

The firm has a market capitalization of $107.97 million, a price-to-earnings ratio of -1.60 and a beta of 1.50. The firm’s fifty day moving average is $2.07 and its 200 day moving average is $1.89.

Seer (NASDAQ:SEER) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.04). The firm had revenue of $3.10 million for the quarter, compared to analyst estimates of $3.55 million. Seer had a negative return on equity of 27.23% and a negative net margin of 478.05%.

Hedge Funds Weigh In On Seer

A number of institutional investors have recently modified their holdings of the stock. Nano Cap New Millennium Growth Fund L P acquired a new stake in Seer in the fourth quarter worth about $1,510,000. Corient Private Wealth LLC acquired a new position in Seer in the fourth quarter valued at approximately $116,000. Quadrature Capital Ltd acquired a new position in Seer in the fourth quarter valued at approximately $101,000. Barclays PLC boosted its stake in Seer by 685.0% in the fourth quarter. Barclays PLC now owns 60,717 shares of the company’s stock valued at $111,000 after acquiring an additional 52,982 shares during the last quarter. Finally, Marshall Wace LLP bought a new position in Seer in the fourth quarter valued at approximately $85,000. 75.20% of the stock is owned by institutional investors.

Seer Company Profile

Seer, Inc is a life sciences company focused on pioneering next-generation proteomics, the large-scale study of proteins and their functions in complex biological systems. By leveraging proprietary nanoparticle-based technology, Seer’s platform enables high-throughput, unbiased protein analysis from biological samples, addressing a critical bottleneck in drug discovery, biomarker research and precision medicine.

The company’s flagship Proteograph Product Suite combines engineered nanoparticle assays with advanced mass spectrometry and bioinformatics pipelines to deliver deep proteomic coverage in a scalable workflow.